Japan approves Alzheimer treatment Leqembi by Eisai and Biogen

Japan's Eisai said on Monday the country's health ministry had approved its Alzheimer treatment Leqembi, co-developed with U.S.-based Biogen. The drug is the first treatment shown to slow progression of the disease for people in the earlier stages of Alzheimer's. ( read original story ...)

Fujitsu to quit Tokyo HQ

PLUS: Micron breaks ground in India; Hong Kong goes for green fintech; Taiwan to launch first sub; and more ASIA IN BRIEF Fujitsu last week announced it will move out of its Tokyo headquarters and ... ( read original story ...)